Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO.

Peng G, Bojadzieva J, Ballinger ML, Li J, Blackford AL, Mai PL, Savage SA, Thomas DM, Strong LC, Wang W.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):837-844. doi: 10.1158/1055-9965.EPI-16-0695. Epub 2017 Jan 30.

PMID:
28137790
2.

Optimal delivery of male breast cancer follow-up care: improving outcomes.

Ferzoco RM, Ruddy KJ.

Breast Cancer (Dove Med Press). 2015 Nov 23;7:371-9. doi: 10.2147/BCTT.S75630. eCollection 2015. Review.

3.

Impact of Genetic Counseling and Testing on Altruistic Motivations to Test for BRCA1/2: a Longitudinal Study.

Garg R, Vogelgesang J, Kelly K.

J Genet Couns. 2016 Jun;25(3):572-82. doi: 10.1007/s10897-015-9911-z. Epub 2015 Nov 18.

4.

Male Breast Cancer: A Study in Small Steps.

Korde LA.

Oncologist. 2015 Jun;20(6):584-5. doi: 10.1634/theoncologist.2015-0174. Epub 2015 May 18. No abstract available.

5.

BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.

Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobágyi GN, Singletary CN, Hashmi SS, Arun BK, Litton JK.

Oncologist. 2015 Jun;20(6):593-7. doi: 10.1634/theoncologist.2014-0425. Epub 2015 May 6.

6.

Pathogenesis, prevention, diagnosis and treatment of breast cancer.

Shah R, Rosso K, Nathanson SD.

World J Clin Oncol. 2014 Aug 10;5(3):283-98. doi: 10.5306/wjco.v5.i3.283. Review.

7.

Establishing a program for individuals at high risk for breast cancer.

Cadiz F, Kuerer HM, Puga J, Camacho J, Cunill E, Arun B.

J Cancer. 2013 Jul 1;4(5):433-46. doi: 10.7150/jca.6481. Print 2013.

8.
9.

Understanding the needs of women considering risk-reducing salpingo-oophorectomy.

Cherry C, Ropka M, Lyle J, Napolitano L, Daly MB.

Cancer Nurs. 2013 May-Jun;36(3):E33-8. doi: 10.1097/NCC.0b013e3182642cb5.

10.

Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families.

Fernández-Rodríguez J, Quiles F, Blanco I, Teulé A, Feliubadaló L, Valle JD, Salinas M, Izquierdo A, Darder E, Schindler D, Capellá G, Brunet J, Lázaro C, Pujana MA.

BMC Cancer. 2012 Mar 8;12:84. doi: 10.1186/1471-2407-12-84.

11.

Predictive models for mutations in mismatch repair genes: implication for genetic counseling in developing countries.

Monteiro Santos EM, Valentin MD, Carneiro F, de Oliveira LP, de Oliveira Ferreira F, Junior SA, Nakagawa WT, Gomy I, de Faria Ferraz VE, da Silva Junior WA, Carraro DM, Rossi BM.

BMC Cancer. 2012 Feb 9;12:64. doi: 10.1186/1471-2407-12-64.

12.

Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.

Kwong A, Wong CH, Suen DT, Co M, Kurian AW, West DW, Ford JM.

World J Surg. 2012 Apr;36(4):702-13. doi: 10.1007/s00268-011-1406-y.

13.

Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.

Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B.

Cancer. 2012 Mar 15;118(6):1515-22. doi: 10.1002/cncr.26428. Epub 2011 Aug 25. Erratum in: Cancer. 2014 Mar 15;120(6):927.

14.

CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry.

Mulligan AM, Pinnaduwage D, Bane AL, Bull SB, O'Malley FP, Andrulis IL.

Cancer. 2011 Apr 1;117(7):1350-9. doi: 10.1002/cncr.25642. Epub 2010 Nov 2.

15.

Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women.

Comen E, Balistreri L, Gönen M, Dutra-Clarke A, Fazio M, Vijai J, Stadler Z, Kauff N, Kirchhoff T, Hudis C, Offit K, Robson M.

Breast Cancer Res Treat. 2011 Jun;127(2):479-87. doi: 10.1007/s10549-010-1215-2. Epub 2010 Oct 19.

16.

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.

Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, Nord AS, Mandell JB, Swisher EM, King MC.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12629-33. doi: 10.1073/pnas.1007983107. Epub 2010 Jun 28.

17.

Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.

Kurian AW, Gong GD, John EM, Miron A, Felberg A, Phipps AI, West DW, Whittemore AS.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1084-91. doi: 10.1158/1055-9965.EPI-08-1090. Epub 2009 Mar 31.

18.

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.

Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakili I, Royer R, Li S, Narod SA.

BMC Cancer. 2009 Mar 19;9:86. doi: 10.1186/1471-2407-9-86.

19.

A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.

Gómez García EB, Oosterwijk JC, Timmermans M, van Asperen CJ, Hogervorst FB, Hoogerbrugge N, Oldenburg R, Verhoef S, Dommering CJ, Ausems MG, van Os TA, van der Hout AH, Ligtenberg M, van den Ouweland A, van der Luijt RB, Wijnen JT, Gille JJ, Lindsey PJ, Devilee P, Blok MJ, Vreeswijk MP.

Breast Cancer Res. 2009;11(1):R8. doi: 10.1186/bcr2223. Epub 2009 Feb 6.

20.

Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States.

Huo D, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, Hope K, Olopade OI.

J Clin Oncol. 2009 Mar 10;27(8):1184-90. doi: 10.1200/JCO.2008.17.5869. Epub 2009 Feb 2. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262.

Supplemental Content

Support Center